Turja Chakrabarti
YOU?
Author Swipe
View article: Risk and protective factors for sudden infant death syndrome (SIDS) in low-resource communities in Kolkata India: a mixed methods exploratory study of semi-structured interviews and survey data
Risk and protective factors for sudden infant death syndrome (SIDS) in low-resource communities in Kolkata India: a mixed methods exploratory study of semi-structured interviews and survey data Open
Sudden Unexpected Infant Death (SUID), Sudden Infant Death Syndrome (SIDS) and infant sleep practices are widely documented and studied in high-resource countries. Knowledge of SUID/SIDS occurrence, risk factors and protective factors in l…
View article: Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer
Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer Open
These findings suggest that ARID1A mutations are critical biomarkers for osimertinib resistance and highlight WEE1 inhibition as a promising therapeutic approach for ARID1A-mutant osimertinib-resistant NSCLC.
View article: Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain me…
View article: Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
View article: Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S9 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Venn diagram depicting co-mutation overlap between KEAP1, SMARCA4, and CDKN2A – KSC genes; survival outcomes according to co-mutation overlap in any of the KSC genes - PFS (B) and OS (C). Only patients whose tumor was profiled with a NG…
View article: Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors …
View article: Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort A
View article: Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
View article: Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - progression-free survival
View article: Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort A
View article: Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
View article: Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S7 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to co-mutation status for (A) CHEK2 and (B) ATRX in the overall mutation-evaluable population.
View article: Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - overall survival
View article: Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - overall survival
View article: Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S10 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Integrated model for patient stratification and clinical outcome prediction with KRAS G12Ci monotherapy in KRASG12C-mutant NSCLC.
View article: Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
View article: Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort B
View article: Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Baseline Patient Characteristics – Cohort B
View article: Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S3 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 (A), SMARCA4 (B), and CDKN2A (C) co-mutation status in Cohorts A and B.
View article: Supplementary Figure S8 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S8 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) Survival outcomes in patients with additional RAS co-alterations (KRAS amplification, other KRAS, NRAS and/or HRAS somatic mutations) in the KSCWT population; B) outcomes according to AKT1/PIK3CA/MTOR/TSC1/2/PTEN co-mutation status for …
View article: Supplementary Figure S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Progression-free survival (left) and overall survival (right) according to TP53 co-mutation status in A) overall cohort, B) cohort A, and C) cohort B.
View article: Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S1 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Clinical outcomes in Cohorts A (left) and B (right). A) progression-free survival; B) overall survival.
View article: Supplementary Table S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
List of major molecular profiling platforms included in the cohort
View article: Supplementary Table S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S6 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
List of major molecular profiling platforms included in the cohort
View article: Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S2 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
A) ORR (left), PFS (middle) and OS (right) in patients with ECOG-PS 0 or 1, at least 1 prior line of therapy for metastatic disease and without untreated brain metastases; B) Survival outcomes in patients with treated or untreated brain me…
View article: Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Figure S5 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Survival outcomes according to KEAP1 and STK11 co-mutation status: A) Cohort A; B) Cohort B; C) further subclassifying KEAP1MUT tumors according to STK11 mutation status; D) PFS and OS according to STK11 co-mutation status in KSCWT tumors …
View article: Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC
Supplementary Table S4 from Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC Open
Multivariable analysis - progression-free survival